LX7101

LX7101

• CAS Number: 1192189-69-7
• UNSPSC Description: LX7101 is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and 50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 has the potential for ocular hypertension and associated glaucoma research[1][2].
• Target Antigen: LIM Kinase (LIMK); PKA; ROCK
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Cytoskeleton;Stem Cell/Wnt;TGF-beta/Smad
• Field of Research: Endocrinology
• Assay Protocol: https://www.medchemexpress.com/LX7101.html
• Purity: 99.75
• Solubility: DMSO : 150 mg/mL (ultrasonic)
• Smiles: NCC1(C(NC2=CC(OC(N(C)C)=O)=CC=C2)=O)CCN(C3=C4C(NC=C4C)=NC=N3)CC1
• Molecular Weight: 451.52
• References & Citations: [1]Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010.|[2]Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Phase 2